• Ahmed Awais Medical Oncology department, SKMCH&RC, Lahore
  • Irfan A Vaziri Consultant Hematologist & Oncologist Medical Director - Callahan Cancer Center Great Plains Health North Platte, NE
  • Benjamin George Consultant Hematologist & Oncologist Vice Chief of Staff Banner MD Anderson at North Colorado Medical Center Greeley, CO




Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.

Patnaik JL, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res 2011;13:R64.

Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 2014;15:1063-93.

Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-41.

Tan TC, Neilan TG, Francis S, et al. Anthracycline-induced cardiomyopathy in adults. Compr Physiol 2015;5:1517-40.

Gorini S, De Angelis A, Berrino L, et al. Chemotherapeutic drugs and mitochondrial dysfunction: Focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev 2018;18:7582730.

Berardi D, Agati L. Cardiovascular adverse reactions after the administration of recombinant human erythropoietin: Light and shade. Minerva Cardioangiol 2012;60:227-36.

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-47.

Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755-64.

Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European association of cardiovascular imaging and the American society of echocardiography. Eur

Heart J Cardiovasc Imaging 2013;14:721-40.

Barros-Gomes S, Herrmann J, Sharon L, et al. Rationale for setting up a cardio-oncology unit: Our experience at mayo clinic. Cardio Oncol 2016;2:5.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: The task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J 2016;37:2768-801.

Kostakou PM, Kouris NT, Kostopoulos VS, et al. Cardio-oncology: A new and developing sector of research and therapy in the field of cardiology. Heart Fail Rev 2019;24:91-100.

Sharalaya Z, Collier P. Prevention of cardiotoxicities with traditional and novel chemotherapeutic agents. Curr Heart Fail Rep 2018;15:260-9.

Lancellotti P, Suter TM, López-Fernández T, et al. Cardio-oncology services: Rationale, organization, and implementation: A report from the ESC cardio-oncology council. Eur Heart J 2018. Doi: 10.1093/eurheartj/ehy453.

How to Cite
Awais A, Vaziri IA, George B. CARDIO-ONCOLOGY – THE NEW KID ON THE BLOCK. J Cancer Allied Spec [Internet]. 2018Sep.30 [cited 2022May26];4(3). Available from: